Zidovudine (AZT)

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Retrovir · 2.1

• • Always with other antiretrovirals; the pediatric dose must not exceed the adult dose. FDA Retrovir · 2.1FDA Retrovir · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: pregnancy registry data show no increase in birth defects over the background rate. FDA Retrovir · 8.1

  “Available data from the APR show no difference in the overall risk of birth defects for zidovudine compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Retrovir · 8.2

  “Risk Summary The Centers for Disease Control and Prevention recommends that HIV‑1‑infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV‑1 infection.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Retrovir · 8.4

  “RETROVIR has been studied in HIV-1-infected pediatric subjects aged at least 6 weeks who had HIV-1-related symptoms or who were asymptomatic with abnormal laboratory values indicating significant HIV-1-related immunosuppression.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Retrovir · 8.5

  “In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.